Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Moodys
AstraZeneca
Baxter
Harvard Business School

Last Updated: January 28, 2022

DrugPatentWatch Database Preview

Claims for Patent: 6,875,904

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 6,875,904
Title: Animal model for identifying agents that inhibit or enhance CTLA4 signaling
Abstract:The present invention relates to a non-human transgenic animal, particularly a knock in mouse, whose genome comprises a heterologous, chimeric CTLA4 gene. The chimeric CTLA4 gene comprises exon 2 of the human CTLA4 gene, exon 1 and exon 4 of the non-human animal, and exon 3 of the CTLA4 gene of the non-human animal, or preferably, exon 3 of the human CTLA4 gene. The invention also relates to methods by which the transgenic mice are used to screen for monoclonal antibodies or other molecules that enhance immunity to tumors and infectious agents by interacting with the human CTLA4 receptor. The transgenic mice of the present invention are also useful for screening for monoclonal antibodies or other molecules that inhibit autoimmunity and transplant rejection.
Inventor(s): Liu; Yang (Columbus, OH), Zheng; Pan (Columbus, OH), Lu; Ping (Columbus, OH), Mosinger; Bedrich (Columbus, OH), May; Ken (Kettering, OH)
Assignee: The Ohio State University Research Foundation (Columbus, OH)
Application Number:09/957,688
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,875,904
Patent Claims:1. A transgenic mouse whose genome comprises a nucleic acid encoding a humanized CTLA4 receptor and whose T cells express the humanized CTLA4 receptor, wherein said humanized CTLA4 receptor comprises the extracellular domain of a human CTLA4 receptor, and said nucleic acid comprises exon 2 of a human CTLA4 receptor gene, and exons 1, 3, and 4, of a mouse or human CTLA4 receptor gene.

2. The transgenic mouse of claim 1, wherein the mouse genome comprises exon 1 and exon 4 of the mouse CTLA4 gene, exon 2 of the human CTLA4 gene, and exon 3 of the mouse or human CTLA4 gene.

3. The transgenic mouse of claim 2, wherein the genome comprises in order, exon 2, intron 2, and exon 3 of the human CTLA4 gene.

Details for Patent 6,875,904

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Sign up for a Free Trial 2020-09-20
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Sign up for a Free Trial 2020-09-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Johnson and Johnson
Moodys
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.